



# Biotech Daily

Monday March 31, 2014

*Daily news on ASX-listed biotechnology companies*

**\* ASX UP, BIOTECH DOWN: CIRCADIAN UP 12.5%, REVA DOWN 30%**

**\* ANALYTICA FINALIZING PERICOACH INCONTINENCE TRAINING TOOL**

**\* PRANA REQUESTS PHASE II ALZHEIMER'S RESULTS TRADING HALT**

**\* IM MEDICAL CLOSER TO WHITE DATA MERGER**

## MARKET REPORT

The Australian stock market was up 0.52 percent on Monday March 31, 2014 with the S&P ASX 200 up 27.9 points to 5,394.8 points.

Ten of the Biotech Daily Top 40 stocks were up, 21 fell, six traded unchanged and three were untraded.

Circadian was the best, up 2.5 cents or 12.5 percent to 22.5 cents with 1,500 shares traded, followed by Compumedics up 10 percent to 11 cents with 455,000 shares traded.

GI Dynamics climbed 4.6 percent; Cellmid was up 3.6 percent; Mesoblast and Patrys rose more than two percent; Acrux, Neuren and Sirtex were up more than one percent; with Nanosonics and Resmed up less than one percent.

Reva led the falls for the second trading day in a row, down 6.5 cents or 29.55 percent to 15.5 cents with 704,819 shares traded (BD: Mar 27, 2014).

Benitec lost 9.75 percent; Impedimed and Universal Biosensors fell more than eight percent; IDT was down 6.25 percent; Phosphagenics fell 5.05 percent; Atcor and Pharmaxis fell four percent or more; Admedus, Bionomics, Genetic Technologies and Viralytics were down more than three percent; Anteo, Antisense, Prima and Psivida shed two percent or more; Alchemia, Clinuvel, QRX and Starpharma were down more than one percent; with Cochlear, CSL and Medical Developments down by less than one percent.

## ANALYTICA

Analytica says it is finalizing testing of its Pericoach intra-vaginal urinary incontinence training tool.

Analytica said that 60 volunteer patients would be involved in the final stage of the usability trial, being conducted in Australia by urinary incontinence specialists.

The company said that the first three phases of the four phase of the usability trials had been completed, providing “valuable data to fine tune the Pericoach system”.

Analytica said that pelvic floor strength measurement data had been tested through the mobile telephone application to the internet database.

The company said that about 12 volunteers had tried the Pericoach system during the three phases, involving physiotherapists specializing in urinary incontinence treatment.

Analytica said that manufacturing was on-track to start in late May 2014 and safety validation testing was being completed.

The company said its US testing agency confirmed that the Pericoach complied with the International Standard ISO 10993 – ‘Biological evaluation of medical devices’ with silicone used in the Pericoach specifically tested for any cytotoxicity, sensitization, irritation and systemic toxicity issues.

Analytica said that the Pericoach had passed all electromagnetic compatibility (EMC) emission requirements, which measured the amount of interference the device caused to other electrical systems nearby, with electrical safety testing to IEC 60601 currently underway.

The company said that applications for Conformité Européenne (CE) mark approval would be lodged when the IEC 60601 electrical safety testing report was received with the current processing time for applications about six to 10 days.

Analytica said a US Food and Drug Administration 510(k) application would be lodged soon after EU approval..

The company said the Pericoach and lithium-ion battery had been declared to be not considered a dangerous good under International Air Transport Association rules, removing any questions about transportation risk.

Analytica said that payment and patient record database systems were completed.

Analytica was up 0.4 cents or 16 percent to 2.9 cents with 6.7 million shares traded.

## PRANA BIOTECHNOLOGY

Prana has requested a trading halt pending an announcement “in relation to the results of its PBT2 ‘Imagine’ Alzheimer’s disease phase II trial”.

Prana began the up-to-40 patient, 12-month, randomized, double-blind, placebo-controlled phase II imaging trial of PBT2 for Alzheimer’s disease in 2012, completed recruitment that year and completed dosing in 2013 (BD: Mar 6, Nov 27, 2012; Dec 9, 2013).

In March 2012, Prana said the primary outcome was to evaluate the effect of PBT2 compared to placebo on brain amyloid levels after 52 weeks of treatment as measured by carbon 11-Pittsburgh imaging compound-B (PiB) positron emission tomography (PET) imaging at 26 and 52 weeks after beginning treatment with PBT2 or the placebo.

The company said at that time that secondary outcomes included the evaluation of the safety and tolerability of PBT2 compared to placebo as measured by capture of vital signs, physical examination, neurological examination, electro-cardiogram, eye examination, blood haematology and biochemistry, urinalysis and recording of adverse events.

The trial details are at: <http://www.anzctr.org.au/ACTRN12611001008910.aspx>.

Trading will resume on April 2, 2014 or on an earlier announcement.

Prana last traded at \$1.04.

## IM MEDICAL

IM Medical says it finalizing the merger agreement with White Data to become a specialist data centre management company (BD: Dec 20, 2013).

IM said the finalization process included confirmation by White Data of the availability of bank finance for the construction of a proposed Brisbane data centre, which would be followed by an extraordinary general meeting for shareholder approval.

In 2013 IM Medical said it would acquire White Data for \$9.1 million of its shares based on a notional issue price of two cents a share.

IM Medical was attempting to commercialize cardiac testing in which the Federal Government reimbursed the tests.

In its most recent significant announcement in June 2012 the company said that it had sold its shareholding in Capitol Health which was going to acquire IM's radiology business (BD: Jun 19, 2012).

Mark Scott Group acquired IM Medical but the company saw a raft of board changes and dissent at meetings, which followed IM's inability to commercialize its Intelliheart cardiac testing system (BD: Jun 20, 2008; Jun 10, 30, Nov 22, 2010; Feb 7, Mar 10, 2011).

IM Medical was unchanged at 0.1 cents.